Opioid exposure in newborns: lessons learned from fetal alcohol spectrum disorder.

The increasing incidence of opioid-exposed pregnancies in the United States is a concerning public health challenge. Analysis of the public health responses to prenatal alcohol exposure may inform future prevention and treatment strategies. Behavioral interventions, improved screening, and prenatal education may be effective measures to reduce prenatal exposure to opioids. Medicaid coverage should be expanded to cover substance misuse treatments for pregnant women.

Prenatal and postnatal exposure risk assessment of chlorinated paraffins in mothers and neonates: Occurrence, congener profile, and transfer behavior.

Gestation and lactation are very sensitive and vulnerable stages for human growth and development. During these two periods, short-chain chlorinated paraffins (SCCPs) and medium-chain chlorinated paraffins (MCCPs) can be transported to neonates via transplacental and breastfeeding transfers, and eventually posing potential adverse effects to neonates. Up to date, no simultaneous investigation of prenatal and postnatal exposure of CPs is reported. To bridge this knowledge gap, we have analyzed SCCPs and MCCPs in 20 complete sets of maternal serum, umbilical cord serum, placenta, and breast milk. The levels of both ∑SCCP and ∑MCCP followed the order of maternal serum > breast milk > cord serum > placenta. The breastfeeding transfer ratios (RBM, ≈ 1.0) of CPs were greater than the corresponding transplacental transfer ratios (RCM, < 1.0), demonstrating the higher transport of CPs during the lactation period. The placental retention/or accumulation ratios (RPM) showed that CPs were effectively retained by the placental barrier. Furthermore, the total exposure amount of SCCPs and MCCPs during the lactation period was> 100 times higher than the gestation exposure amounts. This study helps to better understand the prenatal and postnatal exposure of CPs and provides a solid basis for accurate human health risk assessment of CPs.

Risk Assessment of Neonatal Exposure to Low Frequency Noise Based on Balance in Mice.

General electric devices and ventilation systems are known to generate low frequency noise (LFN) with frequencies of <100 Hz. Previous studies showed that exposure to LFN caused impairments of balance in humans and mice during adulthood. On the other hand, a previous study showed that noise levels in the neonatal intensive care unit (NICU) were greater than those in general home or office environments. Therefore, it is possible that neonates have a potential risk to be exposed to LFN in the NICU. However, the risk of neonatal exposure to LFN remains unclear in humans and mice. In this study, male ICR mice were exposed to LFN at 100 Hz for 4 weeks after birth and then subjected to rotarod and beam crossing tests in order to assess LFN-mediated risk of imbalance during the neonatal period. Exposure to LFN at 70 dB, but not exposure to LFN up to 60 dB, during the neonatal period significantly decreased performance scores for rotarod and beam crossing tests compared to the scores of the control group. The number of calbindin-positive hair cells in the saccule and utricle was decreased in mice exposed to LFN at 70 dB for 4 weeks in the neonatal phase. Cessation of exposure for 10 weeks did not result in recovery of the decreased performance in rotarod and beam crossing tests. Thus, our results suggest that 70 dB is a possible threshold for exposure to LFN for 4 weeks during the neonatal period causing unrecoverable imbalance in mice.

Residual Isocyanates in Medical Devices and Products: A Qualitative and Quantitative Assessment.

We conducted a pilot qualitative and quantitative assessment of residual isocyanates and their potential initial exposures in neonates, as little is known about their contact effect. After a neonatal intensive care unit (NICU) stockroom inventory, polyurethane (PU) and PU foam (PUF) devices and products were qualitatively evaluated for residual isocyanates using Surface SWYPE™. Those containing isocyanates were quantitatively tested for methylene diphenyl diisocyanate (MDI) species, using UPLC-UV-MS/MS method. Ten of 37 products and devices tested, indicated both free and bound residual surface isocyanates; PU/PUF pieces contained aromatic isocyanates; one product contained aliphatic isocyanates. Overall, quantified mean MDI concentrations were low (4,4'-MDI = 0.52 to 140.1 pg/mg) and (2,4'-MDI = 0.01 to 4.48 pg/mg). The 4,4'-MDI species had the highest measured concentration (280 pg/mg). Commonly used medical devices/products contain low, but measurable concentrations of residual isocyanates. Quantifying other isocyanate species and neonatal skin exposure to isocyanates from these devices and products requires further investigation.

Bisphenol A environmental exposure and the detrimental effects on human metabolic health: is it necessary to revise the risk assessment in vulnerable population?

In the last decades, many reports have focused the attention on deleterious effects of novel environmental chemical compounds, including bisphenol A (BPA), on human health. BPA, a common and widely chemical contaminant acting as endocrine disruptor, accumulates in adipose tissue and may affect adipocyte metabolic and inflammatory functions. BPA, at low chronic doses, is now considered as an obesogen compound, and might contribute to the rise of metabolic syndrome, visceral adiposity and diabetes epidemics. The BPA worldwide presence in the environment is responsible for chronic exposure during vulnerable periods, such as foetal and neonatal life. The BPA source of contamination can occur via food, beverage, wastewater, air, dust and soil. BPA, as lipophilic compound, may accumulate into the adipose tissue already during foetal life and may affect adulthood health, through adverse effects on the growth and development of organs and tissues. Thus, based on several studies, it would be crucial to consider further actions aimed to refine risk assessment at least in vulnerable population, such as foetuses, infants and young children, to prevent metabolic diseases and obesity.